This study determines the cost effectiveness of personalized cancer therapy based on the reduction of costs for each treatment cycle for the drug Bortezomib using antineoplastic agents’ preparation in the bio-safety cabinet of the Hematology pharmacy of the UHC “Mother Teresa” Tirana. Bortezomib is used in the Hematology Department for the patients diagnosed with multiple myeloma taking in consideration international treatment protocols. In this study we have evaluated the cost effectiveness of personalized cancer therapy comparing the costs of the same drug, which is Bortezomib, administered in different years to the same patient. The study has been conducted in the period 01.01.2015 – 30.06.2015 (before using the bio- safety cabinet for personalized therapy) and 01.01.2016 – 30.06.2016 (using the bio-safety cabinet for personalized therapy). We have decided to calculate the cost effectiveness with focus to the cost reduction in ALL for the treatment with the same drug and same treatment protocol for each cycle in order to determinate the cost effectiveness of the personalized cancer therapy. Conclusions: The reduction of costs for the same patient for each cycle after using the bio- safety cabinet for Bortezomib varies from 30857.15 ALL – 41142.86 ALL in comparison to the period when we didn´t use the bio-safety cabinet. Further studies are needed to evaluate the full cost effectiveness of personalized cancer therapy, calculating the cost reduction for each patient and each drug prepared in the UHC “Mother Teresa” Tirana. Keywords: cost effectiveness, antineoplastic agents preparations.